Semaglutide API: Hundreds of global shipments recorded over the past year, spanning R&D and commercial volumes
They have emerged as key therapeutic targets in diabetes and obesity research , ranging from GLP-1 analogs like Semaglutide (Ozempic/Wegovy) to dual and triple agonists (Retatrutide) that synergistically enhance glycemic control and promote weight loss
These medications work by mimicking glucagon-like peptide-1, a hormone naturally produced by the body that plays a key role in appetite regulation, digestion, and metabolic function
It is known that peptide 20 potently reversed metabolic disorders in rodent models of obesity and diabetes, characteristic of increased energy expenditure and elevated circulating FGF21 levels as a result of GCGR agonism 22,23
References Lillig, C
The findings, published in The New England Journal of Medicine , highlight the potential of GLP-1 receptor agonism combined with amylin analog therapy to deliver clinically meaningful weight loss beyond currently available treatments